CDMO Scale CorePharma operates 4 FDA- and DEA-registered facilities with 150,000 square feet and an annual capacity of up to 5 billion dosage units, signaling strong capacity for mid- to large-scale manufacturing partnerships and potential for scale-up projects.

End-to-End Solutions As a concept to commercial CDMO, CorePharma offers development, analytical, clinical, manufacturing, and packaging capabilities, presenting opportunities for clients seeking integrated support from early development through commercial launch.

Regulatory Strength Described as having a proven track record of regulatory excellence, CorePharma can be a trusted partner for companies prioritizing regulatory compliance and efficient approvals across diverse therapeutic areas.

Security Challenge Recent ransomware incident highlights cybersecurity risk exposure; engaging with CorePharma may involve offering enhanced security services, incident response collaboration, or ensuring robust data protection as part of a vendor risk assessment.

Financial Profile Revenue in the $100M–$250M range with a leaner employee base (51–200) suggests a mid-market CDMO with potential for flexible partnerships, faster decision cycles, and opportunities to win multi-project or long-term manufacturing agreements.